Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.

Daniel Yick Chin Heng, Aly‐Khan A. Lalani, Pascale Dutailly et al.|Journal of Clinical Oncology|2023

Cited by 0